CardiaTec Biosciences Raises £1.4 Million to Use AI for Cardiovascular Disease Treatments

CardiaTec Biosciences, a Cambridge-based AI drug target discovery company, has secured £1.4 million in pre-seed funding

The round was led by Laidlaw Scholars Ventures and APEX Ventures, with participation from Crista Galli Ventures, o2h ventures, and Cambridge Enterprise

This marks the first investment for Laidlaw Scholars Ventures, a new VC fund established by the Laidlaw Foundation

CardiaTec aims to use AI to identify new treatments for cardiovascular diseases, which is the leading cause of death globally.